Chen Ziyi, Zhao Yi
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Maternal and Child Healthcare Hospital of Shandong Province Affiliated to Qingdao University, Jinan, Shandong, China.
Front Pharmacol. 2025 Jan 15;15:1437022. doi: 10.3389/fphar.2024.1437022. eCollection 2024.
Triple-negative breast cancer (TNBC) is a type of breast cancer with lack the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is the most aggressive breast cancer and the most difficult to treat due to its poor response to treatments and extremely invasive characteristics. The typical treatment for TNBC frequently results in relapse because of the lack of particular treatment choices. It is urgent to focus on identifying a workable and effective target for the treatment of TNBC. Cancer metastasis is significantly influenced by epithelial-mesenchymal transition (EMT). Ferroptosis is an iron-dependent cell death form, and changes its key factor to affect the proliferation and metastasis of TNBC. Several reports have established associations between EMT and ferroptosis in TNBC metastasis. Furthermore, non-coding RNA (ncRNA), which has been previously described, can also control cancer cell death and metastasis. Thus, in this review, we summarize the correlation and pathways among the ferroptosis, EMT, and ncRNAs in TNBC metastasis. Also, aim to find out a novel strategy for TNBC treatment through the ncRNA-ferroptosis-EMT axis.
三阴性乳腺癌(TNBC)是一种缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)表达的乳腺癌。它是最具侵袭性的乳腺癌,由于对治疗反应不佳且具有极强的侵袭性,因而也是最难治疗的乳腺癌。由于缺乏特定的治疗选择,TNBC的典型治疗常常导致复发。迫切需要专注于确定一种可行且有效的TNBC治疗靶点。癌症转移受到上皮-间质转化(EMT)的显著影响。铁死亡是一种铁依赖性细胞死亡形式,改变其关键因子会影响TNBC的增殖和转移。多项报告已证实EMT与TNBC转移中的铁死亡之间存在关联。此外,先前已描述过的非编码RNA(ncRNA)也可控制癌细胞的死亡和转移。因此,在本综述中,我们总结了TNBC转移中铁死亡、EMT和ncRNA之间的相关性及途径。同时,旨在通过ncRNA-铁死亡-EMT轴找到一种TNBC治疗的新策略。